Engineering and Development

President and Chief Executive Officer

Chief Financial Officer

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

Soft Tissue Allograft Market to Grow at 7.5% CAGR from 2025-2029

Axogen Insider Sold Shares Worth $584,074, According to a Recent SEC Filing

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Biostatistician – Clinical Trials (Drug/Biologic)

Axogen is committed to building and maintaining a strong and gratifying company culture that fosters professional growth. The Biostatistician is responsible for the design and conduct of clinical research studies, including developing statistical analysis plans, performing statistical analysis, and reporting study results.

Director, Total Rewards & HRIS

Senior Human Resources Manager

Sign up with Google

Sign in with Google